The cooperation integrates Bio-Rads market leading digital PCR innovation and track record in molecular oncology, assay style and advancement with AHNs cancer-care knowledge, medical information, and patient samples collected through the AHN Cancer Institutes Moonshot program. Together, through this project, Bio-Rad and AHN aim to generate clinical proof to support the use of Bio-Rads Droplet Digital PCR Systems, including the QX600 ™ ddPCR System, in regular MRD monitoring of clients with a range of strong growth types.” AHN is devoted to finding ingenious methods to treat our cancer clients based on their unique genomic characteristics to accomplish the finest result possible within our Living Health design,” stated William A. LaFramboise, PhD, Professor and Chief Genomics Technology Officer, AHN Cancer Institute.